NASDAQ:RZLT Rezolute (RZLT) Stock Price, News & Analysis $3.92 -0.28 (-6.67%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$3.99 +0.07 (+1.79%) As of 11/20/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rezolute Stock (NASDAQ:RZLT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rezolute alerts:Sign Up Key Stats Today's Range$3.86▼$4.2350-Day Range$3.58▼$4.8752-Week Range$1.07▼$11.16Volume2.47 million shsAverage Volume1.61 million shsMarket Capitalization$379.18 millionP/E RatioN/ADividend YieldN/APrice Target$11.67Consensus RatingModerate Buy Company Overview Rezolute, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar. The company’s lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia. Rezolute is led by CEO Nevan Elam. Its drug candidates remain in development and are not approved treatments.AI Generated. May Contain Errors. Read More Rezolute Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreRZLT MarketRank™: 3.08488469019 of 5 starsRezolute scored higher than 62% of companies evaluated by MarketBeat, and ranked 377th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRezolute has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialRezolute has a consensus price target of $11.67, representing about 197.6% upside from its current price of $3.92.Amount of Analyst CoverageRezolute has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rezolute's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rezolute are expected to grow in the coming year, from ($0.66) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rezolute is -5.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rezolute is -5.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRezolute has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.51% of the float of Rezolute has been sold short.Short Interest Ratio / Days to CoverRezolute has a short interest ratio ("days to cover") of 14.93, which indicates bearish sentiment.Change versus previous monthShort interest in Rezolute has recently decreased by 3.49%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRezolute does not currently pay a dividend.Dividend GrowthRezolute does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.61 News SentimentRezolute has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Rezolute this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for RZLT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows5 people have added Rezolute to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rezolute insiders have not sold or bought any company stock.Percentage Held by Insiders15.05% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rezolute's insider trading history. Receive RZLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RZLT Stock News HeadlinesRezolute (NASDAQ:RZLT) Stock Price Crosses Below Two Hundred Day Moving Average - Time to Sell?November 21 at 3:22 AM | americanbankingnews.comRezolute, Inc.: Still Holding Out For Ersodetug Approval - Which May Be UnderstandableNovember 20 at 3:22 PM | seekingalpha.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 21 at 1:00 AM | Weiss Ratings (Ad)Will Rezolute's Upcoming Tumor Hyperinsulinism Trial Data Uplift The Stock?November 19 at 8:46 AM | rttnews.comRezolute (NASDAQ:RZLT) Stock Price Expected to Rise, Wedbush Analyst SaysNovember 19 at 2:18 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Intellia Therapeutics (NTLA)November 18 at 2:49 PM | theglobeandmail.comRezolute reports phase 3 upLIFT study meets primary efficacy endpoint in tumor hyperinsulinismNovember 13, 2026 | msn.comRezolute stock rises on positive Phase 3 upLIFT trial resultsNovember 13, 2026 | finance.yahoo.comSee More Headlines RZLT Stock Analysis - Frequently Asked Questions How have RZLT shares performed this year? Rezolute's stock was trading at $2.36 on January 1st, 2026. Since then, RZLT stock has increased by 66.1% and is now trading at $3.92. How were Rezolute's earnings last quarter? Rezolute, Inc. (NASDAQ:RZLT) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01. Who are Rezolute's major shareholders? Top institutional shareholders of Rezolute include State Street Corp (1.89%), Blue Owl Capital Holdings LP (0.97%), Goldman Sachs Group Inc. (0.92%) and Russell Investments Group Ltd. (0.27%). Insiders that own company stock include Young-Jin Kim, Nevan C Elam, Nevan C Elam, Daron Evans, Wladimir Hogenhuis, Wladimir Hogenhuis, Sunil Ratilal Karnawat, Nerissa Kreher and Brian Kenneth Roberts. View institutional ownership trends. How do I buy shares of Rezolute? Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rezolute own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rezolute investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Micron Technology (MU), Palantir Technologies (PLTR), Marvell Technology (MRVL), Red Cat (RCAT) and Tesla (TSLA). Company Calendar Last Earnings11/05/2026Today11/21/2026AGM 202612/02/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 RZLT's financial health is in the Green zone, according to TradeSmith. RZLT has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RZLT CIK1509261 Webwww.rezolutebio.com Phone(650) 206-4507FaxN/AEmployees58Year Founded2010Price Target and Rating Average Price Target for Rezolute$11.67 High Price Target$20.00 Low Price Target$6.00 Potential Upside/Downside+197.6%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.59 million Net MarginsN/A Pretax MarginN/A Return on Equity-72.24% Return on Assets-65.90% Debt Debt-to-Equity RatioN/A Current Ratio9.92 Quick Ratio9.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book4.40Miscellaneous Outstanding Shares96,730,000Free Float82,171,000Market Cap$379.18 million OptionableOptionable Beta0.65 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:RZLT) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.